Xiaoming Hou

机构：Gansu University of Traditional Chinese Medicine, Fifth Tianjin Central Hospital, First Hospital of Lanzhou University, Lanzhou University · ORCID：0000-0002-8521-749X

发表论文 94 篇 · 总被引 1171 次 · h-index 22

代表论文

• A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC (2023 · Journal of Thoracic Oncology · 被引 63)
• Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer (2024 · Research · 被引 29)
• Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy (2024 · Journal of Nanobiotechnology · 被引 25)
• Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death (2024 · Life Sciences · 被引 19)
• Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma (2024 · Oncogene · 被引 15)
• Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC). (2024 · Journal of Clinical Oncology · 被引 9)